Overview

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19

Status:
Recruiting
Trial end date:
2021-04-21
Target enrollment:
Participant gender:
Summary
The host response against the coronavirus 2 (SARS-CoV-2) appears to be mediated by a 'cytoquine storm' developing a systemic inflammatory mechanism and an acute respiratory distress syndrome (ARDS), in the form of a bilateral pneumonitis, requiring invasive mechanical ventilation (IMV) in an important group of patients. In terms of preventing progression to the critical phase with the consequent need of admission to the intensive care units (ICU), it has been recently proposed that this inflammatory cytoquine-mediated process can be safely treated by a single course of ultra-low radiotherapy (RT) dose < 1 Gy. The main purpose of the study was to analyze the efficacy of ultra low-dose pulmonary RT, as an anti-inflammatory intention in patients with SARS-Cov-2 pneumonia with a poor or no response to standard medical treatment and without IMV.
Phase:
N/A
Details
Lead Sponsor:
Fundacion GenesisCare
Collaborators:
Hospital La Milagrosa
Hospital Vithas Valencia Consuelo
Treatments:
Azithromycin
Dalteparin
Heparin
Heparin, Low-Molecular-Weight
Hydroxychloroquine
Lopinavir
Piperacillin
Piperacillin, Tazobactam Drug Combination
Ritonavir
Tazobactam
Tinzaparin